asthenia/cancer mamar

Linkul este salvat în clipboard

Alegeți tipul de sortare

Pagină 1 din 549 rezultate

Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND The objectives of this pilot study were to evaluate the safety and efficacy of the central nervous system stimulant methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel. METHODS Patients with early breast cancer who presented asthenia >3 on the

Association between asthenia and nutritional status, lean body mass, anemia, psychological status, and tumor mass in patients with advanced breast cancer.

Numai utilizatorii înregistrați pot traduce articole

Sixty-four consecutive patients with advanced breast cancer were included in a study designed to determine the prevalence of asthenia and its association with other clinical features. The Asthenia Score (AS, the average of four tests designed by our group to assess asthenia) was 59 +/- 9 for

Analysis of factors related to arm weakness in patients with breast cancer-related lymphedema.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE The aim of this study was to evaluate the ratio of significant weakness in the affected arm of breast cancer-related lymphedema patients to their unaffected side. Another purpose was to identify factors related to arm weakness and physical function in patients with breast cancer-related

Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.

Numai utilizatorii înregistrați pot traduce articole

Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We

Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model.

Numai utilizatorii înregistrați pot traduce articole

Muscle weakness and cachexia are significant paraneoplastic syndromes of many advanced cancers. Osteolytic bone metastases are common in advanced breast cancer and are a major contributor to decreased survival, performance, and quality of life for patients. Pathologic fracture caused by osteolytic

Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.

Numai utilizatorii înregistrați pot traduce articole

Breast cancer bone metastases often cause a debilitating non-curable condition with osteolytic lesions, muscle weakness and a high mortality. Current treatment comprises chemotherapy, irradiation, surgery and anti-resorptive drugs that restrict but do not revert bone destruction. In metastatic

[Determination of a vector of therapy for weakness in incurable breast cancer patients based on the level of inflammatory response].

Numai utilizatorii înregistrați pot traduce articole

The weakness is one of the negative factors that degrade cancer patients’ quality of life. The nature of weakness may be multifactorial but among mechanisms of development of weakness a syndrome of chronic inflammation plays a crucial role. Therapy aimed at reducing of inflammation degree allows

Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy.

Numai utilizatorii înregistrați pot traduce articole

Several recently published studies describe moderate to severe cognitive dysfunction in breast cancer survivors who were treated with adjuvant chemotherapy 1-5 years before undergoing extensive neuropsychological testing. While these studies are hypothesis-generating and preliminary given their

Asthenia in breast cancer.

Numai utilizatorii înregistrați pot traduce articole

Effectiveness of exercise programmes on shoulder mobility and lymphoedema after axillary lymph node dissection for breast cancer: systematic review.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE This article is a report of a review of the effectiveness of exercise programmes on shoulder mobility and lymphoedema in postoperative patients with breast cancer having axillary lymph node dissection, as revealed by randomized controlled trials. BACKGROUND Breast cancer is the most common

Breast cancer in European Union: an update of screening programmes as of March 2014 (review).

Numai utilizatorii înregistrați pot traduce articole

Breast cancer, a major cause of female morbidity and mortality, is a global health problem; 2008 data show an incidence of ~450,000 new cases and 140,000 deaths (mean incidence rate 70.7 and mortality rate 16.7, world age-standardized rate per 100,000 women) in European Union Member States.

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.

Numai utilizatorii înregistrați pot traduce articole

Olaparib (AZD2281) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor with antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with homologous recombination deficiency. In this dose-finding study, patients were randomized to olaparib 10, 30, 100, 200 or 400 mg

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND This exploratory study examined the pharmacokinetics, safety, and antitumor activity of sunitinib plus docetaxel in patients with HER-2-negative advanced breast cancer. METHODS Patients with HER-2-negative disease who had received prior adjuvant anthracycline-based therapy received

Does architectural lighting contribute to breast cancer?

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE There is a growing interest in the role that light plays on nocturnal melatonin production and, perhaps thereby, the incidence of breast cancer in modern societies. The direct causal relationships in this logical chain have not, however, been fully established and the weakest link is an

Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer.

Numai utilizatorii înregistrați pot traduce articole

A phase II study of carboplatin and etoposide as salvage polychemotherapy in metastatic, infiltrating breast carcinoma was carried out with 25 multiply pretreated patients. Six of 25 patients (24%) had a partial response that lasted an average of 3.5 months; of the six responders, four had undergone

Anterior
1
2
3
4
5
6
...
36
37
Următor →

Alăturați-vă paginii
noastre de facebook

Herbal & Natural Medicine

Cea mai completă bază de date cu plante medicinale susținută de știință

Funcționează în 55 de limbi
Cure pe bază de plante susținute de știință
Recunoașterea ierburilor după imagine
Harta GPS interactivă - etichetați ierburile în locație (în curând)
Citiți publicațiile științifice legate de căutarea dvs.
Căutați plante medicinale după efectele lor
Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele

Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate